SCHEMBL4648884

SCHEMBL4648884

O=C(O)C=C1CCCCN1

nearest known ligand 0.43

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 1/20 0.43
ITGB1 P05556 1/20 0.43
ITGAV P06756 1/20 0.43
ITGA4 P13612 1/20 0.43
FKBP5 Q13451 1/20 0.39
CRBN Q96SW2 1/20 0.39
NPC1 O15118 1/20 0.32
HPGD P15428 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
OR51E2 Q9H255 1/20 0.31
KDM4E B2RXH2 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18796727 1.00 ITGB3 (0.43) ITGB3ITGB1ITGAVITGA4FKBP5
SCHEMBL13545399 0.98 ITGB3 (0.42) ITGB3ITGB1ITGAVITGA4FKBP5
SCHEMBL16107849 0.93
SCHEMBL12963772 0.93
SCHEMBL16107526 0.93
SCHEMBL22435208 0.84 FKBP5 (0.34) ITGB3ITGB1ITGAVITGA4FKBP5
SCHEMBL11722783 0.81 FKBP5 (0.38) FKBP5CRBNOR51E2
SCHEMBL7989075 0.81 FKBP5 (0.38) FKBP5CRBNOR51E2
SCHEMBL11727451 0.79 FKBP5 (0.37) FKBP5CRBNNPC1HPGDRAB9A
SCHEMBL22435286 0.78 OR51E2 (0.32) ITGB3ITGB1ITGAVITGA4OR51E2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111868031-B Process for the preparation of N-alkoxycarbonylpiperidine derivatives and intermediates therefor 有机合成药品工业株式会社 2023-10-03 CN claimed
EP-1400511-B1 Methods of producing n-alkoxycarbonylpiperidine derivatives and intermediates therefor YUKI GOSEI YAKUHIN KOGYO KK (JP) 2008-09-03 EP claimed
US-6900326-B2 Method of producing N-alkoxycarbonylpiperidine derivative, new compound as raw material therefor, and method of producing the compound YUKI GOSEI KOGYO CO., LTD. (JP) 2005-05-31 US claimed
US-20040063953-A1 Method of producing N-alkoxycarbonylpiperidine derivative, new compound as raw material therefor, and method of producing the compound YUKI GOSEI KOGYO CO., LTD. (JP) 2004-04-01 US claimed
EP-1400511-A1 Methods of producing n-alkoxycarbonylpiperidine derivatives and intermediates therefor YUKI GOSEI KOGYO CO., LTD. (JP) 2004-03-24 EP claimed
CN-111868031-B Process for the preparation of N-alkoxycarbonylpiperidine derivatives and intermediates therefor 有机合成药品工业株式会社 2023-10-03 CN disclosed
CN-111868031-A Process for producing N-alkoxycarbonylpiperidine derivative and intermediate therefor 有机合成药品工业株式会社 2020-10-30 CN disclosed
WO-2019142900-A1 METHOD FOR PRODUCING N-ALKOXYCARBONYLPIPERIDINE DERIVATIVE, AND INTERMEDIATE THEREFOR 有機合成薬品工業株式会社 2019-07-25 WO disclosed
WO-2018021977-A1 GLYCINE METABOLISM MODULATORS AND USES THEREOF AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2018-02-01 WO disclosed
WO-2017072796-A1 2-PYRIDONE BASED COMPOUNDS USEFUL AS POTENTIAL PHOSPHODIESTERASE3A (PDE3A)INHIBITORS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-05-04 WO disclosed
CN-102949357-B A kind of tablet of prasugrel hydrobromide SHANDONG NEW TIME PHARMACEUTICAL Co.,Ltd. (CN) 2016-01-27 CN disclosed
CN-104173316-A Capsule of hydrobromic acid prasugrel SHANGDONG NEW TIME PHARM PROD 2014-12-03 CN disclosed
CN-102949357-A Prasugrel hydrobromide tablet SHANGDONG NEW TIME PHARM PROD 2013-03-06 CN disclosed
EP-1400511-B1 Methods of producing n-alkoxycarbonylpiperidine derivatives and intermediates therefor YUKI GOSEI YAKUHIN KOGYO KK (JP) 2008-09-03 EP disclosed
WO-2008059862-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE 2-(2'-PIPERIDINYL)ACETATE UBE INDUSTRIES, LTD. (JP) 2008-05-22 WO disclosed
US-6900326-B2 Method of producing N-alkoxycarbonylpiperidine derivative, new compound as raw material therefor, and method of producing the compound YUKI GOSEI KOGYO CO., LTD. (JP) 2005-05-31 US disclosed
US-20040063953-A1 Method of producing N-alkoxycarbonylpiperidine derivative, new compound as raw material therefor, and method of producing the compound YUKI GOSEI KOGYO CO., LTD. (JP) 2004-04-01 US disclosed
EP-1400511-A1 Methods of producing n-alkoxycarbonylpiperidine derivatives and intermediates therefor YUKI GOSEI KOGYO CO., LTD. (JP) 2004-03-24 EP disclosed
WO-1999029705-A9 SIALYL LEWIS X AND SIALYL LEWIS A GLYCOMIMETICS GLYCOMED INC (US) 1999-11-11 WO disclosed
WO-1999029705-A2 SIALYL LEWIS X AND SIALYL LEWIS A GLYCOMIMETICS GLYCOMED INCORPORATED (US) 1999-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063953-A1 Method of producing N-alkoxycarbonylpiperidine derivative, new compound as raw material therefor, and method of producing the compound ORMDL3, MRPS18A, ACSL3 ITGB3 2625/4885ITGB1 1375/4885ITGAV 856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.